Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter

Official Title: “Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter”

Antibiotics in patients with acute respiratory tract infections in primary care in consideration of procalcitonin as additive parameter.

The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.

Intervention(s) in this Clinical Trial

• Other: laboratory value procalcitonin
  • A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is not recommended, patient shall not take antibiotic. In case of "retention of decision": patient may take the antibiotic. B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is recommended, patient has to be informed about. In case of "retention of decision": no change.

Primary Measures

• days with significant impairment due to acute respiratory tract infection
  • Time Frame: 14 to 28 days after infection
    Safety Issue?: Yes

Secondary Measures

• number of antibiotic prescriptions
  • Time Frame: 28 days
    Safety Issue?: Yes

Inclusion Criteria:

• 18 years or older
• Informed consent
• Respiratory tract infection based on the clinical judgement of the primary care physician

Exclusion Criteria:

• Antibiotic pretreatment in previous 14 days
• Portal hypertension
• Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks
• Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)
• Peritoneal dialysis
• Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid
• Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Hannover Medical School Other

Overall Clinical Trial Officials and Contacts

Olaf Burkhardt, Dr. Principal Investigator Medical School Hannover  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00688610

Study ID Number: HannoverPro II

ClinicalTrials.gov Identifier: NCT00688610

Health Authority: Germany: Ethics Commission